Preclinical Cardiotoxicity

hERG potassium-channel blockade is examined because it can delay ventricular repolarization, the electrical recovery phase of the heart. This delay may appear as QT prolongation in relevant assessments, making hERG activity an important electrophysiological signal during compound evaluation. Results can influence compound selection and prompt closer examination of exposure levels and other cardiac endpoints before clinical testing.

Electrical disturbances and mechanical dysfunction represent different forms of cardiac injury. A compound may affect ventricular repolarization and QT duration, impair contractility, or produce structural myocardial injury. Measuring these endpoints together provides a broader view of potential harm than relying on one signal alone, supporting more informed development and risk-mitigation decisions.

Interpretation depends on the type of cardiac effect, the exposure at which it appears, and whether findings are supported across complementary models. Electrophysiology, contractility, biomarkers, imaging, and pathology contribute different evidence. Considering these results together helps determine whether a finding warrants compound deprioritization, dose or exposure assessment, or a specific risk-mitigation strategy.

These models provide different levels and types of evidence. Cell-based assays can examine specific cardiac responses, engineered tissues can evaluate function in a more organized cardiac context, and animal studies can integrate electrophysiology, biomarkers, imaging, and pathology. Using the models together strengthens interpretation and supports translation from laboratory observations to clinical safety decisions.

Evaluation begins with targeted cardiac testing and expands across complementary systems as findings require. Cell-based assays, engineered cardiac tissues, and animal studies can examine electrophysiology, contractility, and structural injury. Investigators then integrate exposure information with biomarkers, imaging, and pathology to guide compound selection, characterize risk, and decide whether mitigation is needed before clinical testing.

Dose and exposure assessment places cardiac findings in the context of the amount of intervention associated with an observed effect. This information helps distinguish findings that may constrain development from those that can be managed through selection of a compound, adjustment of exposure considerations, or other risk-mitigation strategies. It also supports more meaningful translation to clinical safety planning.

Electrophysiological measurements can reveal delayed ventricular repolarization and QT prolongation, while functional assessments address impaired contractility. Biomarkers, imaging, and pathology add evidence about cardiac or structural myocardial injury. Combining these measurements helps connect a functional signal with potential tissue damage and gives development teams a more complete basis for safety interpretation.

Cardiac findings discovered before clinical testing can influence which compounds advance and how their risks are managed. The evidence supports decisions about compound selection, dose and exposure assessment, and mitigation strategies. Its medical value lies in integrating laboratory models and multiple readouts to improve the translation of potential cardiac hazards into clinical safety decisions.